5-Methanesulfonamido-6-(2,4-difluorothiophenyl)-1-indanone - patents, research & applications

36Patents

36Research papers

0Patents - last 3 years

0Papers - last 3 years

Who owns the IP

The organizations most actively patenting around this compound, ranked by referenced patent volume.

#	Assignee	Patents
1	Perrigo Co PLC	12
2	Alkermes PLC	10
3	GSK PLC	5
4	Nicox SA	1

Where innovation is concentrated

Patent classifications ranked by volume reveal the technical domains with the most active filing.

#	Code	Area	Patents
1	`A61K`	Medicinal preparations	34
2	`A61P`	Therapeutic activity (drug indications)	34
3	`B82Y`	Nanotechnology	3
4	`A61F`		1
5	`B23K`		1

6	`C07C`	Acyclic and carbocyclic compounds	1
7	`C07D`	Heterocyclic compounds	1
8	`C07J`		1
9	`C07K`	Peptides	1

AI mapped opportunity space

This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.

See Cypris in action

Representative patents

The filings that best characterise the patent activity around this compound, most-referenced first.

Title	Year	Assignee	Cited by
NANOPARTICULATE COMPOSITIONS HAVING A PEPTIDE AS A SURFACE STABILIZER	2005	Perrigo Co PLC	45
Nanoparticulate compositions having a peptide as a surface stabilizer	2011	Alkermes PLC	29
METHODS OF TREATING BEHAVIORIAL AND/OR MENTAL DISORDERS	2014		19
NOVEL METAXALONE COMPOSITIONS	2005	Perrigo Co PLC	32
Reduction of flake-like aggregation in nanoparticulate active agent compositions	2016	Alkermes PLC	11

Who's driving the science

The most-published authors working with this compound, alongside their primary affiliations.

#	Author	Affiliation	Papers
1	Jane A. Mitchell	Royal Brompton Hospital	4
2	Paola Patrignani	University of Chieti-Pescara	4
3	Giovanna Santini	University of Chieti-Pescara	3
4	Maria G. Sciulli	University of Chieti-Pescara	3
5	Robert J. Gordon	Merck Canada Inc. (Canada)	3

6	Daniel Guay	Merck Canada Inc. (Canada)	3
7	Chi-Chung Chan	Merck Canada Inc. (Canada)	3
8	Anita Greco	University of Chieti-Pescara	2
9	Maria T. Rotondo	University of Chieti-Pescara	2
10	Timothy D. Warner	William Harvey Research Institute	2

Research leaders

This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.

See Cypris in action

The literature that defines it

The most-cited papers anchoring the scientific record for this compound.

Title	Year	Cited by	Topic
Pharmacology of a selective cyclooxygenase-2 inhibitor, L-745,337: a novel nonsteroidal anti-inflammatory agent with an ulcerogenic sparing effect in rat and nonhuman primate stomach.	1995	314	Inflammatory mediators and NSAID effects
Effects of inhibition of prostaglandin endoperoxide synthase‐2 in chronic gastro‐intestinal ulcer models in rats	1998	286	Helicobacter pylori-related gastroenterology studies
Spinal antinociceptive effects of cyclooxygenase inhibition during inflammation: Involvement of prostaglandins and endocannabinoids	2009	118	Pain Mechanisms and Treatments
Effects of the novel anti‐inflammatory compounds, N‐[2‐(cyclohexyloxy)‐4‐nitrophenyl] methanesulphonamide (NS‐398) and 5‐methanesulphonamido‐6‐(2, 4‐difluorothiophenyl)‐1‐indanone (L‐745, 337), on the cyclo‐oxygenase activity of human blood prostaglandin endoperoxide synthases	1995	83	Inflammatory mediators and NSAID effects
Effect of cyclooxygenase and nitric oxide synthase inhibitors on tumor growth in mouse tumor models with and without cancer cachexia related to prostanoids.	2000	83	Inflammatory mediators and NSAID effects

Frequently asked questions

Common questions about this compound's patent and research landscape, answered from the underlying data.

What is the molecular formula and weight of this compound?

5-Methanesulfonamido-6-(2,4-difluorothiophenyl)-1-indanone has a molecular formula of C16H13F2NO3S3 and a molecular weight of 401.4608.

Which companies hold the most patents related to this compound?

Perrigo Co PLC holds 12 patents and Alkermes PLC holds 10 patents related to this compound, making them the leading patent assignees in this space.

What research institutions have published papers on this compound?

Multiple research institutions are represented in the publication record. The University of Chieti-Pescara has contributed substantially through authors including Paola Patrignani, Giovanna Santini, Maria G. Sciulli, Anita Greco, and Maria T. Rotondo. The Royal Brompton Hospital, William Harvey Research Institute, and Merck Canada Inc. have also contributed research.

What patent protection classes are most commonly associated with this compound?

The compound is predominantly classified under CPC subclass A61K (pharmaceutical preparations) and A61P (specific therapeutic activity of chemical compounds or preparations), each appearing in 34 patents. Nanoparticulate technology applications also appear in 3 patents classified under B82Y.

In what year was patent activity on this compound highest?

Patent activity was highest in 2018 with 3 patents filed. Other notable years include 2016 and 2017 with 2 and 1 patents respectively. No patent filings were recorded in the last 3 years based on the available data.